Moderna
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IN
IE
US
US
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
Moderna (MRNA) Business News
Track Moderna in real time with a live news feed covering Moderna stock news, official press releases, company announcements, and an archive of historical Moderna news. ...more
-
CalendarDateSuMoTuWeThFrSaSelected FilterNo selection
Moderna (MRNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
European Commission Approves MRNA's COVID-19-Influenza Combo Shot
European Commission Approves MRNA's COVID-19-Influenza Combo Shot
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
Moderna wins EU approval for combined flu, COVID shot for older adults
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
Moderna to Present at Upcoming Conferences in May 2026
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
Stock Market Today (LIVE): PPI Beats Fear, But Oil Risks Loom; Novo's OpenAI Deal Lifts Shares
Meet the 2 Formerly Down-and-Out Stocks That Are Outperforming the S&P 500 This Year. Are They Still a Buy?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Moderna (MRNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:01 AM | Friday | Apr 24, 2026
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
Moderna (MRNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks Investment ResearchModerna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
Zacks Investment ResearchIn the most recent trading session, Moderna (MRNA) closed at $55.6, indicating a +2.53% shift from the previous trading day.
Read full article
European Commission Approves MRNA's COVID-19-Influenza Combo Shot
Zacks Investment ResearchModerna wins EU approval for its COVID-19-flu combo shot mCombriax, backed by strong phase III data showing superior immune response vs standalone vaccines.
Read full article
European Commission Approves MRNA's COVID-19-Influenza Combo Shot
Zacks Investment ResearchModerna wins EU approval for its COVID-19-flu combo shot mCombriax, backed by strong phase III data showing superior immune response vs standalone vaccines.
Read full article
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
AccesswireModerna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 - June 2 in Chicago, IL. The presentation details are as follows: Oral Presentation: Abstract #9500: Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 studySession Type/Title: Oral Abstract Session - Melanoma/Skin CancersData & Time: June 1, 8:00 AM - 11:00 AM CTPresenter: Matteo S.
Read full article
Moderna wins EU approval for combined flu, COVID shot for older adults
ReutersModerna said on Tuesday the European Commission had granted marketing authorization for a combination vaccine for the prevention of influenza and COVID-19 in adults 50 years of age and older.
Read full article
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
AccesswiremCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized product mCOMBRIAX will be made available in the European Union, subject to national regulatory and access procedures CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for mCOMBRIAX® (mRNA-1083), the Company's mRNA combination vaccine for active immunization for the prevention of influenza disease and COVID-19 caused by SARS-CoV-2 in individuals 50 years of age and older. This marketing authorization follows the positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) and is valid in all 27 European Union member states, as well as Iceland, Liechtenstein and Norway.
Read full article
Moderna to Present at Upcoming Conferences in May 2026
AccesswireCAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: BofA Securities 2026 Healthcare Conference, on Tuesday, May 12th at 11:20am PT RBC 2026 Global Healthcare Conference, on Tuesday, May 19th at 10:00 am ET Bernstein's 42nd Annual Strategic Decisions Conference, Thursday, May 28th at 10:00am ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
AccesswireThe U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ (TPS> 1%) CAMBRIDGE, MA / ACCESS Newswire / April 17, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present data from a Phase 1/2 study of mRNA-4359, an investigational cancer antigen therapy, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, on April 17-22, 2026. The presentation reports safety, efficacy and translational data from a Phase 2 dose-expansion cohort of the Phase 1/2 study (NCT05533697), which evaluated mRNA-4359 + pembrolizumab as a first-line therapy in patients with locally advanced or metastatic melanoma.
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
AccesswireCAMBRIDGE, MA / ACCESS Newswire / April 15, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, May 1,2026 to report its first quarter 2026 financial results, and provide a corporate update.
Read full article
Stock Market Today (LIVE): PPI Beats Fear, But Oil Risks Loom; Novo's OpenAI Deal Lifts Shares
Fool - Investing NewsTop insights from the latest market news from Tuesday, April 14, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
Read full article
Meet the 2 Formerly Down-and-Out Stocks That Are Outperforming the S&P 500 This Year. Are They Still a Buy?
The Motley FoolIn an uncertain market, investors have rushed to get in on these players seen as “safer” investments. They operate in the areas of healthcare and retail, selling treatments and products that are essential -- this offers the potential for revenue stability.
Read full article
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Zacks Investment ResearchWhy investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read full article